Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
10 mai 2023 06h30 HE
|
Beam Therapeutics
Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites...
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
27 mars 2023 07h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
21 mars 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
15 mars 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
01 mars 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
28 févr. 2023 06h30 HE
|
Beam Therapeutics
Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base...
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
07 févr. 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
09 janv. 2023 06h30 HE
|
Beam Therapeutics
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in...
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
10 déc. 2022 10h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...